Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial.

zapnometinib (ATR-002) - Atriva Therap

http://www.ncbi.nlm.nih.gov/pubmed/38106555

Antoni Torres; Dennis Neuschwander; Ganesh Manudhane; Gernot Rohde; Hans Prozesky; Martin Bauer; Martin Witzenrath; Oana Sandulescu; Oliver Planz; Stephan Stenglein; Tim Overend; Winfried Koch

Dec 18, 2023